Ventyx Biosciences — Investor Presentation (January 2025)
40 slides from Ventyx Biosciences's investor presentation, Jan 14, 2025
Slide 1: Corporate Presentation January 2025
Exhibit 99.2 CORPORATE PRESENTATION January 2025
Slide 2: Forward Looking Statements
Forward Looking Statements Ventyx Biosciences, Inc. (“Ventyx” or the “Company”) cautions you that statements contained in this presentation regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations. Su
Slide 3: Company Highlights
Company Highlights NLRP3 inhibition represents a paradigm shift in the treatment of autoimmune, inflammatory and neurodegenerative disorders via upstream regulation of key cytokines (e.g., IL-1, IL-18, IL-6) VTX2735 and VTX3232 demonstrate potential best-in-class profiles: low nanomolar potency; pro
Slide 4: Experienced Leadership Team
Experienced Leadership Team Executive Team Raju Mohan, PhD Mark Forman, MD, PhD Matthew Moore John Nuss, PhD CHIEF EXECUTIVE OFFICER, CHIEF MEDICAL OFFICER CHIEF OPERATING OFFICER CHIEF SCIENTIFIC OFFICER FOUNDER Board Of Directors Sheila Gujrathi, PhD Raju Mohan, PhD Onaiza Cadoret-Manier EXECUTIVE
Slide 5: Internally Discovered Clinical-Stage Pipeline
Internally Discovered Clinical-Stage Pipeline Addressing Autoimmune, Inflammatory and Neurodegenerative Diseases with High Unmet Need TARGET PROGRAM PRECLINICAL PHASE 1 PHASE 2 PHASE 3 NEXT ANTICIPATED MILESTONES VTX2735 Ph 2 data H2 2025 Recurrent Pericarditis Peripheral NLRP3 VTX3232 Ph 2 data H1
Slide 6: NLRP3 Inhibition
NLRP3 Inhibition Broad potential in inflammatory diseases
Slide 7: NLRP3 Inflammasome: A Key Component of Innate Immunity
NLRP3 Inflammasome: A Key Component of Innate Immunity Dysregulation Linked to a Broad Range of Inflammatory Diseases INFLAMMASOMES are activated by molecular hallmarks of infection or cellular injury NLRP3 mediates release of proinflammatory cytokines IL-1β and IL-18 and drives a form of cell death
Slide 8: NLRP3 is a High Value Therapeutic Target
NLRP3 is a High Value Therapeutic Target Broad Potential Across Systemic and CNS Inflammatory Disease VTX2735 VTX3232 Systemic Diseases Neuroinflammatory Diseases NLRP3 inhibition has therapeutic potential in a broad NLRP3 activation (inhibition) has been linked to a range of systemic diseases, part
Slide 9: VTX2735 Peripheral NLRP3 Inhibitor
VTX2735 Peripheral NLRP3 Inhibitor
Slide 10: VTX2735: Potent and Selective Peripheral NLRP3 Inhibitor
VTX2735: Potent and Selective Peripheral NLRP3 Inhibitor Phase 2 Ready for Systemic Inflammatory Diseases POTENT & SELECTIVE NONCLINICAL & PHASE 1 PACKAGE • hu WB IC (IL-1β) = 80 nM • Demonstrated pharmacodynamic effects and in 50 vivo efficacy in rodent models • No inhibition of other • High exposu
Slide 11: VTX2735 Open-Label Trial in CAPS (FCAS)
VTX2735 Phase 2 Open-Label Trial in CAPS (FCAS) Trial Design • CAPS is an ultra rare condition driven by gain of function mutations in NLRP3 gene; FCAS is the most common subtype • Following washout of SoC, VTX2735 dosed for 14 days in two treatment periods (TP1 and TP2, 28 days total) • Key endpoin
Slide 12: Treatment with VTX2735 Drives Reductions in Disease Activity
Treatment with VTX2735 Drives Reductions in Disease Activity Disease Activity as Assessed by Key Symptom Score (KSS) and General Well-Being KEY SYMPTOM SCORE (0-10)* GENERAL WELL-BEING (0-10)* Daily mean of five symptom scores “Considering all the ways FCAS affects you, please rate how you are doing
Slide 13: VTX2735 Biomarker Changes
VTX2735 Biomarker Changes Reductions in IL-6, hsCRP and SAA Observed as Expected with NLRP3 Inhibition • The pleiotropic cytokine IL-6 induces acute-phase reactant proteins, including C-reactive protein (CRP) and Serum amyloid A (SAA) • Treatment with VTX2735 reduced plasma IL-6, hsCRP, and SAA in p
Slide 14: Conclusions from the Trial of VTX2735 in FCAS Patients
Conclusions from the Phase 2 Trial of VTX2735 in FCAS Patients Clinical Proof of Concept Achieved in CAPS Patients VTX2735 was well-tolerated; all adverse events VTX2735 showed categorized as mild or moderate and resolved without clinically-meaningful treatment interruption effects on disease activi
Slide 15: VTX2735 is a Phase 2 Ready Peripheral NLRP3 Inhibitor
VTX2735 is a Phase 2 Ready Peripheral NLRP3 Inhibitor BIOLOGIC-LIKE ACTIVITY IN CAPS TRIAL HIGHLY POTENT & SELECTIVE • Structurally unique, selective inhibitor of NLRP3 • Concentration dependent suppression of IL-1β ex vivo • Potent inhibitor of NLRP3 with IC = 80 nM 50 in human whole blood assay •
Slide 16: Attractive Opportunity for NLRP3 in Recurrent Pericarditis
Attractive Opportunity for NLRP3 in Recurrent Pericarditis De-risked Mechanism and Efficient Path to Market 1 Recurrent pericarditis is a ~40,000 patient U.S. prevalent population with recurrent pericarditis debilitating autoinflammatory Autoinflammatory process characterized by IL-1 release conditi
Slide 17: Phase 2 Trial in Participants with Recurrent Pericarditis
Phase 2 Trial in Participants with Recurrent Pericarditis Designed to Efficiently Achieve Clinical Proof of Concept in RP • Phase 2 trial evaluating the effects of VTX2735 in participants with active recurrent pericarditis • Acute symptoms of RP (pain, elevated hsCRP) despite standard therapy • Meas
Slide 18: VTX3232 CNS-Penetrant NLRP3 Inhibitor
VTX3232 CNS-Penetrant NLRP3 Inhibitor
Slide 19: VTX3232: Potent and Selective CNS-Penetrant NLRP3 Inhibitor
VTX3232: Potent and Selective CNS-Penetrant NLRP3 Inhibitor RATIONALLY DESIGNED AND OPTIMIZED FOR CNS EXPOSURE In Vitro Profile In Vivo Profile Pharmaceutics • Hu WB IC (IL-1β) = 15 nM • Safe and well-tolerated in • Single polymorph 50 Phase 1 Study • Mu WB IC (IL-1β) = 94 nM • BCS Class 1 50 • Equa
Slide 20: VTX3232 Efficacy in Neuroinflammation Models
VTX3232 Efficacy in Neuroinflammation Models MOUSE NEUROINFLAMMATION MODEL LPS-PRIMED HUMAN MICROGLIA ✱✱✱✱✱ Inhibition of caspase-1 activation Potent inhibition of induced IL-1β & IL-18 (directly downstream of NLRP3) selective vs TNFα VTX3232 activity translates to CNS-relevant assays and models Sou
Slide 21: VTX3232 Phase 1 SAD and 14-Day MAD Trial in Healthy Volunteers
VTX3232 Phase 1 SAD and 14-Day MAD Trial in Healthy Volunteers Generally well-tolerated following single- and multiple- dose administration VTX3232 achieved • No dose-limiting toxicities optimal exposures in • All treatment emergent adverse events considered mild or moderate Phase 1 with favorable s
Slide 22: VTX3232 Phase 1 SAD and MAD Pharmacokinetics
VTX3232 Phase 1 SAD and 14 Day MAD Pharmacokinetics SINGLE ASCENDING DOSE MULTIPLE ASCENDING DOSE Dose-related, linear exposure from 1 mg to 80 mg 3 mg QD achieves 24 h IL-1β IC coverage 50 Source: Ventyx internal data. SAD: single ascending dose. MAD: multiple ascending dose. huWB: human whole bloo
Slide 23: VTX3232 Whole Blood Ex Vivo IL-1b Stimulation Assay
VTX3232 Whole Blood Ex Vivo IL-1b Stimulation Assay Potent Target Engagement Demonstrated At Doses ≥3 mg QD DATA SUMMARY • Blockade of NLRP3 mediated IL-1β secretion is maintained at Day 14 with repeat dosing • Maximal inhibition achieved at doses of 10 mg QD and higher 1. Lower Limit of Quantitatio
Slide 24: VTX3232 Pharmacokinetics in Cerebrospinal Fluid (CSF)
VTX3232 Pharmacokinetics in Cerebrospinal Fluid (CSF) Comparable exposures in both plasma and CSF MATCHED PLASMA & CSF EXPOSURE IN MAD COHORTS DATA SUMMARY • 40 mg QD exceeds CSF IC for 24 h, achieving 90 robust target coverage for NLRP3 in microglia for neuroinflammatory conditions Source: Ventyx i
Slide 25: VTX3232 Effects on Inflammatory Biomarkers
VTX3232 Effects on Inflammatory Biomarkers Reduction in hsCRP and IL-6 Comparable to that Achieved by Canakinumab (IL-1β mAb) PLASMA hsCRP PLASMA IL-6 CSF IL-6 Systemic inflammation biomarker IL-6 lowered by as much as 46% in plasma hsCRP lowered by as much as 55% 1. Day 14 pre dose samples not avai
Slide 26: Conclusions from the Phase 1 Trial of VTX3232 in NHV
Conclusions from the Phase 1 Trial of VTX3232 in NHV Potentially Class-leading Safety and Efficacy Profile for Neuroinflammatory Diseases DATA SUMMARY 40 MG QD DOSE: DATA PREDICT • Well-tolerated in healthy TARGET COVERAGE LOW EFFICACIOUS DOSES volunteers • Robust target coverage achieved in the pla
Slide 27: VTX3232: Optimally Engineered to Target Neuroinflammatory Diseases
VTX3232: Optimally Engineered to Target Neuroinflammatory Diseases PK & PD PROFILE POTENT & SELECTIVE • Structurally unique • T½ = ~17 h with high free fraction • K < 1 nM to NLRP3 NACHT domain • High CNS penetration; human Kp,uu = 0.5 d • IC = 13 nM hu WB, 2.7 nM in microglia • Data predict trough
Slide 28: VTX3232 Has Potential for Disease Modification in Parkinson's Disease
VTX3232 Has Potential for Disease Modification in Parkinson’s Disease Strong Mechanistic Rationale and High Unmet Need LARGE ADDRESSABLE STRONG BIOLOGIC HIGH UNMET NEED MARKET RATIONALE • ~1 million U.S. patient • Neuroinflammation is • >$4B annual market for prevalent population central to Parkinso
Slide 29: Rationale for Targeting NLRP3 in Parkinson's Disease (PD)
Rationale for Targeting NLRP3 in Parkinson’s Disease (PD) Neuroinflammation May Play a Central Role in Disease Pathogenesis There is a growing body of evidence for NLRP3 inhibition as a potential disease-modifying approach that may prevent dopaminergic neurodegeneration and clinical symptoms NLRP3 i
Slide 30: Phase 2 Trial in Participants with Early Parkinson's Disease
Phase 2 Trial in Participants with Early Parkinson’s Disease Disease-Relevant Biomarkers and Exploratory Neuroimaging • Conducting a Phase 2 safety and biomarker trial assessing NLRP3-, inflammatory, and disease- relevant biomarkers, with exploratory neuroimaging § Impact on relevant plasma and CSF
Slide 31: NLRP3 as a Target in Obesity and Obesity-Related Metabolic Disease
NLRP3 as a Target in Obesity and Obesity-Related Metabolic Disease BODY WEIGHT • Obesity is a chronic inflammatory condition associated with release of NLRP3-related cytokines such as IL-1β and IL-6 § This inflammation may drive a range of metabolic disorders, including insulin resistance, diabetes,
Slide 32: Phase 2 Trial in Obese Participants with Cardiometabolic Risk Factors
Phase 2 Trial in Obese Participants with Cardiometabolic Risk Factors Measuring Key Inflammatory Biomarkers and Changes in Body Composition • Conducting a Phase 2 trial in obese participants with cardiometabolic risk factors, exploring a broad panel of cardiometabolic and inflammatory endpoints: § I
Slide 33: Tamuzimod (VTX002) S1P1 Receptor Modulator for Ulcerative Colitis
Tamuzimod (VTX002) S1P1 Receptor Modulator for Ulcerative Colitis
Slide 34: Tamuzimod Phase 2 Study in Moderate-to-Severe UC
Tamuzimod Phase 2 Study in Moderate-to-Severe UC Designed to Serve as the First of Two Pivotal Trials KEY ELIGIBILITY CRITERIA ENDPOINTS • Patients with moderately to severely active UC as • Primary Endpoint: Clinical remission at Week 13 as defined by the Modified (3-component) Mayo Score defined b
Slide 35: Overview of Tamuzimod Induction Data
Overview of Tamuzimod Induction Data Robust Week 13 Clinical Remission with Differentiated Complete Endoscopic Remission Key Takeaways from Tamuzimod CLINICAL REMISSION (PRIMARY) ENDOSCOPIC REMISSION (MES=0) Week 13 Data ∆ = 22% ∆ = 17% p=0.001 p=0.018 Competitive week 13 clinical remission with 1 ∆
Slide 36: Induction Subgroup Analysis: Advanced Therapy Prior Use
Induction Subgroup Analysis: Advanced Therapy Prior Use Clinical and Endoscopic Remission in both advanced therapy naïve and advanced therapy experienced subgroups CLINICAL REMISSION ENDOSCOPIC REMISSION Advanced Therapy Advanced Therapy Advanced Therapy Advanced Therapy Experienced Experienced Naïv
Slide 37: Preliminary Open-Label Extension Data
Preliminary Open-Label Extension Data Further improvement in clinical and endoscopic remission rates at OLE week 39 % absolute endpoint rate (clinical or endoscopic remission) in induction dose arm at 13 weeks 1 2 1 % CLINICAL REMISSION AT OLE WEEK 39 % ENDOSCOPIC REMISSION AT OLE WEEK 39 BY INDUCTI
Slide 38: Endoscopic Remission is a Consensus Long-Term Treatment Goal
Endoscopic Remission is a Consensus Long-Term Treatment Goal Current therapeutic outcomes remain disappointing: Tamuzimod has demonstrated the potential to set a new bar CURRENT ENDOSCOPIC REMISSION OUTCOMES TAMUZIMOD PROFILE The vast majority of patients on advanced therapy fail to reach Induction
Slide 39: Tamuzimod (VTX002) Program Status
Tamuzimod (VTX002) Program Status OLE/LTE data continue to support the differentiated profile of tamuzimod in ulcerative colitis LTE phase completed mid 2024; data presented at UEGW in October 2024 Tamuzimod is Phase 3 ready (clinical, CMC, regulatory) • End of Phase 2 meeting with FDA completed; EM
Slide 40: Internally Discovered Clinical-Stage Pipeline
Internally Discovered Clinical-Stage Pipeline Addressing Autoimmune, Inflammatory and Neurodegenerative Diseases with High Unmet Need TARGET PROGRAM PRECLINICAL PHASE 1 PHASE 2 PHASE 3 NEXT ANTICIPATED MILESTONES VTX2735 Ph 2 data H2 2025 Recurrent Pericarditis Peripheral NLRP3 VTX3232 Ph 2 data H1
Ventyx Biosciences — Investor Presentation (January 2025) on 6ix